2-Hydroxy Arachidonic Acid: A New Non-Steroidal Anti-Inflammatory Drug

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Lopez, Daniel H ^a   Fiol deRoque, Maria A ^b   Noguera Salvà, Maria A ^b   Terés, Silvia ^a   Campana, Federica ^c   Piotto, Stefano ^c   Castro, José A ^b   Mohaibes, Raheem J ^b   Escribá, Pablo V ^b   Busquets, Xavier ^b  

^a Lipopharma Therapeutics SL   (Spain)

^b UNIVERSITAT DE LES ILLES BALEARS   (Spain)

^c UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYARACHIDONIC ACID; CORTISONE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; IBUPROFEN; INDUCIBLE NITRIC OXIDE SYNTHASE; NEW DRUG; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CATALYSIS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; EXPERIMENTAL MOUSE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MICROGLIA; MOUSE; NONHUMAN; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ARACHIDONIC ACIDS; CELL LINE; CELL SURVIVAL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DRUG EVALUATION, PRECLINICAL; HUMANS; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MOLECULAR DOCKING SIMULATION; NITRIC OXIDE SYNTHASE TYPE II; PROTEOLYSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84883162823     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072052     Document Type: Article

References (39)

1. Tronstad KJ, Berge K, Berge RK, Bruserud P., (2003) Modified fatty acids and their possible therapeutic targets in malignant diseases. Expert Opin Ther Targets 7: 663-667.
2. Brash AR, (2001) Arachidonic acid as a bioactive molecule. J Clin Invest 107: 1339-1345.
3. Medzhitov R, (2008) Origin and physiological roles of inflammation. Nature 454: 428-435.
4. Uozumi N, Kita Y, Shimizu T, (2008) Modulation of Lipid and Protein Mediators of Inflammation by Cytosolic Phospholipase A2α during Experimental Sepsis. J Immunol 181: 3558-3566.
5. Smith WL, DeWitt D, Garavito RM, (2000) Cyclooxygenases: Structural, Cellular, and Molecular Biology. Annu Rev Biochem 69: 145-182.
6. Fitzpatrick FA, Soberman R, (2001) Regulated formation of eicosanoids. J Clin Invest 107: 1347-1351.
7. Soberman RJ, Christmas P, (2003) The organization and consequences of eicosanoid signaling. J Clin Invest 111: 1107-1113.
8. Moncada S, Higgs A, (1993) The L-arginine-nitric oxide pathway. N Engl J Med 329: 2002-2012.
9. Guzik TJ, Korbut R, Adamek-Guzik T, (2003) Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol 54: 469-487.
10. Scott DL, Wolfe F, Huizinga TWJ, (2010) Rheumatoid arthritis. Lancet 376: 1094-1108.
11. Djukanović R, Roche WR, Wilson JW, Beasley CR, Twentyman OP, et al. (1990) Mucosal Inflammation in asthma. Am Rev Respir Dis 142: 434-457.
12. De Rose V, (2002) Mechanisms and markers of airway inflammation in cystic fibrosis. Eur Respir J 19: 333-340.
13. Mantovani A, Allavena P, Sica A, Balkwill F, (2008) Cancer-related inflammation. Nature 454: 436-444.
14. Eikelenboom P, Veerhuis R, Scheper W, Rozemuller AJM, vanGool WA, et al. (2006) The significance of neuroinflammation in understanding Alzheimer's disease. J Neural Transm 113: 1685-1695.
15. Furse KE, Pratt DA, Porter NA, Lybrand TP, (2006) Molecular dynamics simulations of arachidonic acid complexes with COX-1 and COX-2: insights into equilibrium behavior. Biochemistry 45: 3189-3205.
16. Krieger E, Darden T, Nabuurs S, Finkelstein A, Vriend G, (2004) Making optimal use of empirical energy functions: force-field parameterization in crystal space. Proteins 57: 678-683.
17. Berendsen HJC, Postma JPM, van Gunsteren WF, Di Nola A, Haak JR, (1984) Molecular dynamics with coupling to an external bath. J Chem Phys 81: 3684-3689.
18. Duan Y, Wu C, Chowdhury S, Lee MC, Xiong G, et al. (2003) A Point-Charge Force Field for Molecular Mechanics Simulations of Proteins. J Comput Chem 24: 1999-2012.
19. Jakalian A, Jack DB, Bayly CI, (2002) Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation. J Comput Chem 23: 1623-1641.
20. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, et al. (1998) Automated Docking Using a Lamarckian Genetic Algorithm and Empirical Binding Free Energy Function. J Comput Chem 19: 1639-1662.
21. Parr RG, Yang W (1989) Density-Functional Theory of Atoms and Molecules. International series of monographs on chemistry 10. Oxford University Press. New York.
22. Delley B, (2000) From molecules to solids with the DMol3 approach. J Chem Phys 113: 7756-7764.
23. Mosmann T, (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.
24. Bowling SA, Clarke JD, Liu Y, Klessig DF, Dong X, (1997) The cpr5 mutant of Arabidopsis expresses both NPR1-dependent and NPR1-independent resistance. Plant Cell 9: 1573-84.
25. Gomes A, Fernandes E, Silva AMS, Pinto DCGA, Santos CMM, et al. (2009) Anti-inflammatory potential of 2-styrylchromones regarding their interference with arachidonic acid metabolic pathways. Biochem Pharm 78: 171-177.
26. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, et al. (1982) Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal Biochem 126: 131-138.
27. Food & Drug Administration, USA website. Guidance for Industry. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. Available: http://www.fda.gov/cder/guidance/index.htm, http://www.fda.gov/downloads/Drugs/Guidances/UCM078932.pdf. Accessed 2013 Jul 16.
28. Barrios-Rodiles M, Tiraloche G, Chadee K, (1999) Lipopolysaccharide Modulates Cyclooxygenase-2 Transcriptionally and Posttranscriptionally in Human Macrophages Independently from Endogenous IL-1ß and TNF-α. J Immunol 163: 963-969.
29. Mbonye UR, Yuan Ch, Harris CE, Sidhu RS, Song I, et al. (2008) Two Distinct Pathways for Cyclooxygenase-2 protein degradation. J Biol Chem 283: 8611-8623.
30. Kendrew JC, Bodo G, Dintzis HM, Parrish RG, Wyckoff H, et al. (1958) A three-dimensional model of the myoglobin molecule obtained by X-ray analysis. Nature 181: 662-666.
31. Perutz MF, Rossmann MG, Cullis AF, Muirhead H, Will G, et al. (1960) Structure of haemoglobin: a three-dimensional Fourier synthesis at 5.5-A resolution obtained by X-ray analysis. Nature 185: 416-422.
32. Moore JM, Peattie DA, Fitzgibbon MJ, Thomson JA, (1991) Solution structure of the major binding protein for the immunosuppressant FK506. Nature 351: 248-250.
33. Rao P, Knaus EE, (2008) Evolution of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Cyclooxygenase (COX) Inhibition and Beyond. J Pharm Pharmaceut Sci 11: 81-110.
34. Kim SU, de Vellis J, (2005) Microglia in health and disease. J Neurosci Res 81: 302-313.
35. Ohata T, Fukuda K, Takahashi M, Sugimura T, Wakabayashi K, (1997) Suppression of nitric oxide production in lipopolysaccharide-stimulated macrophage cells by omega 3 polyunsaturated fatty acids. Jpn J Cancer Res 88: 234-237.
36. Tran TA, McCoy MK, Sporn MB, Tansey MG, (2008) The synthetic triterpenoid CDDO-methyl ester modulates microglial activities, inhibits TNF production, and provides dopaminergic neuroprotection. J Neuroinflammation 5: 14.
37. Wen J, Ribeiro R, Zhang YJ, (2011) Specific PKC isoforms regulate LPS-stimulated iNOS induction in murine microglial cells. J Neuroinflammation 8: 38.
38. Xu L, Han C, Lim K, Wu T, (2008) Activation of Cytosolic Phospholipase A2α through Nitric Oxide-induced S-Nitrosylation. Involvement of inducible nitric oxide synthase and cycloxygenase-2. J Biol Chem 283: 3077-3087.
39. Eads D, Hansen RL, Oyegunwa AO, Cecil CE, Culver CA, et al. (2009) Terameprocol, a methylated derivative of nordihydroguaiaretic acid, inhibits production of prostaglandins and several key inflammatory cytokines and chemokines. J Inflamm (Lond) 6: 2.